Scienture, BlinkRx announce strategic collaboration to expand access to Arbli

Scienture (SCNX) announced a strategic collaboration to expand national access to Arbli, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Arbli is expected to be available on the BlinkRx platform in Q1 2026. With BlinkRx, 52% more patients start therapy and remain on their medication 40% longer as prescribed. “Arbli represents a meaningful advancement for patients who need a ready-to-use oral suspension of losartan potassium,” commented Narasimhan Mani, President and co-CEO of Scienture. “BlinkRx removes friction in the patient journey, from reducing administrative barriers and accelerating therapy initiation to improving adherence, which translates into greater prescription volume, longer duration on therapy, lower access costs, and broader patient affordability and reach.”